The pathogenesis of the antiphospholipid syndrome

New England Journal of Medicine

Volumn 368, Issue 24, 2013, Pages 2335-

  Million, Matthieu ^a   Raoult, Didier ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR RESPONSE; CAUSAL ATTRIBUTION; CELL ACTIVATION; DISEASE ASSOCIATION; ENDOCARDITIS; ENDOTHELIUM CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; PRIORITY JOURNAL; Q FEVER; VALVULAR HEART DISEASE;

EID: 84878844774     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1304515     Document Type: Letter

References (4)

1. Million M, Walter G, Bardin N, et al. IgG anticardiolipin antibodies and progression to Q fever endocarditis. Clin Infect Dis 2013 March 26 (Epub ahead of print).
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
3. Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2011;124:215-24.
4. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004;2:1558-63. (Pubitemid 40186171)